194 related articles for article (PubMed ID: 31380273)
1. Five Technologies for Detecting the
Chen YL; Lin CC; Yang SC; Chen WL; Chen JR; Hou YH; Lu CC; Chow NH; Su WC; Ho CL
Front Oncol; 2019; 9():631. PubMed ID: 31380273
[TBL] [Abstract][Full Text] [Related]
2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
3. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy.
Filipits M; Kainz V; Sebek V; Zach H; On Behalf Of The Liquid Biopsy Collaborative Study Group
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444638
[TBL] [Abstract][Full Text] [Related]
5. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
[TBL] [Abstract][Full Text] [Related]
6. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
Nishikawa S; Kimura H; Koba H; Yoneda T; Watanabe S; Sakai T; Hara J; Sone T; Kasahara K; Nakao S
J Thorac Dis; 2018 Mar; 10(3):1431-1439. PubMed ID: 29707292
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
[TBL] [Abstract][Full Text] [Related]
8. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.
Li H; Wang J; Zhang G; Li Y; Lin L; Yang H; Zhou J; Zhang L; Lv D
J Thorac Dis; 2020 Mar; 12(3):550-557. PubMed ID: 32274120
[TBL] [Abstract][Full Text] [Related]
9. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
[TBL] [Abstract][Full Text] [Related]
10. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Gao W; He J; Jin SD; Xu J; Yu TF; Wang W; Zhu Q; Dai H; Wu H; Liu YQ; Shu YQ; Guo RH
Onco Targets Ther; 2019; 12():9495-9504. PubMed ID: 31819477
[TBL] [Abstract][Full Text] [Related]
11. Detection of
Siggillino A; Ulivi P; Pasini L; Reda MS; Chiadini E; Tofanetti FR; Baglivo S; Metro G; Crinó L; Delmonte A; Minotti V; Roila F; Ludovini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297595
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of molecular methods for plasma detection of EGFR mutations in non-small cell lung cancer.
Lee K; Lim S; Lee YG; Kim H; Lee S; Yu HJ; Park H; Kwon MJ; Woo HY
Asia Pac J Clin Oncol; 2022 Dec; 18(6):595-604. PubMed ID: 35098673
[TBL] [Abstract][Full Text] [Related]
13. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
Wang Z; Chen R; Wang S; Zhong J; Wu M; Zhao J; Duan J; Zhuo M; An T; Wang Y; Bai H; Wang J
PLoS One; 2014; 9(11):e110780. PubMed ID: 25405807
[TBL] [Abstract][Full Text] [Related]
14. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
Watanabe M; Kawaguchi T; Isa S; Ando M; Tamiya A; Kubo A; Saka H; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Sakamoto K; Matsumura A; Koh Y
Clin Cancer Res; 2015 Aug; 21(15):3552-60. PubMed ID: 25882755
[TBL] [Abstract][Full Text] [Related]
16. Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
Wang L; Guo Q; Yu W; Qiao L; Zhao M; Zhang C; Hu X; Yang G; Xiong L; Lou J
Lung Cancer; 2017 Dec; 114():31-37. PubMed ID: 29173762
[TBL] [Abstract][Full Text] [Related]
17. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
Pan G; Chen K; Yu X; Sheng J; Fan Y
Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
[TBL] [Abstract][Full Text] [Related]
18. Development, validation, and comparison of gene analysis methods for detecting
Hanibuchi M; Kanoh A; Kuramoto T; Saito T; Tobiume M; Saijo A; Kozai H; Kondo M; Morizumi S; Yoneda H; Kagawa K; Ogino H; Sato S; Kawano H; Otsuka K; Toyoda Y; Nokihara H; Goto H; Nishioka Y
Oncotarget; 2019 Jun; 10(38):3654-3666. PubMed ID: 31217900
[TBL] [Abstract][Full Text] [Related]
19. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
[TBL] [Abstract][Full Text] [Related]
20. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
